Alexander M Bernhardt1, Benedikt Schrage, Ines Schroeder, Georg Trummer, Dirk Westermann, Hermann Reichenspurner. 1. Department for Cardiovascular Surgery, University Heart & Vascular Center Hamburg; Department of Cardiology, University Heart & Vascular Center Hamburg; Department of Anaesthesiology, LMU Hospital Munich; Department of Cardiovascular Surgery, Heart Center, Faculty of Medicine, University of Freiburg.
Abstract
BACKGROUND: Veno-venous extracorporeal membrane oxygenation (VV-ECMO) and veno-arterial extracorporeal membrane oxygenation (VA-ECMO), also known as extracorporeal life support (ECLS), can both be used to treat patients with acute pulmonary or cardiovascular failure. METHODS: This review is based on publications retrieved by a selective search in PubMed on the topics of cardiogenic shock and acute pulmonary failure, also known as the acute respiratory distress syndrome (ARDS), as well as on ECMO. Attention was given chiefly to randomized, controlled trials and guidelines. RESULTS: Initial findings from prospective, randomized trials of VV-ECMO are now available. Trials of ECLS therapy are now in progress or planned. A meta-analysis of two randomized, controlled trials of VV-ECMO for ARDS revealed more frequent survival 90 days after randomization among patients treated with VV-ECMO, compared to the control groups (36% vs. 48%; RR = 0.75 [95% confidence interval 0.6; 0.94]). For selected patients, after evaluation of the benefit-risk profile, VV-ECMO is a good treatment method for severe pulmonary failure, and ECLS for cardiogenic shock and resuscitation. The goal is to secure the circulation so that native heart function can be stabilized in the patient's further course or a permanent left-heart support system can be implanted, or else to support lung function until recovery. CONCLUSION: ECMO is a valid option in selected patients when conservative treatment has failed.
BACKGROUND: Veno-venous extracorporeal membrane oxygenation (VV-ECMO) and veno-arterial extracorporeal membrane oxygenation (VA-ECMO), also known as extracorporeal life support (ECLS), can both be used to treat patients with acute pulmonary or cardiovascular failure. METHODS: This review is based on publications retrieved by a selective search in PubMed on the topics of cardiogenic shock and acute pulmonary failure, also known as the acute respiratory distress syndrome (ARDS), as well as on ECMO. Attention was given chiefly to randomized, controlled trials and guidelines. RESULTS: Initial findings from prospective, randomized trials of VV-ECMO are now available. Trials of ECLS therapy are now in progress or planned. A meta-analysis of two randomized, controlled trials of VV-ECMO for ARDS revealed more frequent survival 90 days after randomization among patients treated with VV-ECMO, compared to the control groups (36% vs. 48%; RR = 0.75 [95% confidence interval 0.6; 0.94]). For selected patients, after evaluation of the benefit-risk profile, VV-ECMO is a good treatment method for severe pulmonary failure, and ECLS for cardiogenic shock and resuscitation. The goal is to secure the circulation so that native heart function can be stabilized in the patient's further course or a permanent left-heart support system can be implanted, or else to support lung function until recovery. CONCLUSION: ECMO is a valid option in selected patients when conservative treatment has failed.
Authors: Guido Michels; Tobias Wengenmayer; Christian Hagl; Christian Dohmen; Bernd W Böttiger; Johann Bauersachs; Andreas Markewitz; Adrian Bauer; Jan-Thorsten Gräsner; Roman Pfister; Alexander Ghanem; Hans-Jörg Busch; Uwe Kreimeier; Andreas Beckmann; Matthias Fischer; Clemens Kill; Uwe Janssens; Stefan Kluge; Frank Born; Hans Martin Hoffmeister; Michael Preusch; Udo Boeken; Reimer Riessen; Holger Thiele Journal: Clin Res Cardiol Date: 2018-09-04 Impact factor: 5.460
Authors: Peter Moritz Becher; Benedikt Schrage; Christoph R Sinning; Bastian Schmack; Nina Fluschnik; Michael Schwarzl; Christoph Waldeyer; Diana Lindner; Moritz Seiffert; Johannes T Neumann; Alexander M Bernhardt; Uwe Zeymer; Holger Thiele; Hermann Reichenspurner; Stefan Blankenberg; Raphael Twerenbold; Dirk Westermann Journal: Circulation Date: 2018-11-13 Impact factor: 29.690
Authors: Evgenij Potapov; Antonio Loforte; Federico Pappalardo; Michiel Morshuis; David Schibilsky; Daniel Zimpfer; Daniel Lewin; Julia Riebandt; Konstantin Von Aspern; Julia Stein; Matteo Attisani; Assad Haneya; Faiz Ramjankhan; Dirk W Donker; Ulrich P Jorde; Radi Wieloch; Rafael Ayala; Jochen Cremer; Mauro Rinaldi; Andrea Montisci; Michael Borger; Artur Lichtenberg; Jan Gummert; Diyar Saeed Journal: J Card Surg Date: 2021-02-05 Impact factor: 1.620
Authors: Demetris Yannopoulos; Jason Bartos; Ganesh Raveendran; Emily Walser; John Connett; Thomas A Murray; Gary Collins; Lin Zhang; Rajat Kalra; Marinos Kosmopoulos; Ranjit John; Andrew Shaffer; R J Frascone; Keith Wesley; Marc Conterato; Michelle Biros; Jakub Tolar; Tom P Aufderheide Journal: Lancet Date: 2020-11-13 Impact factor: 79.321
Authors: Giles J Peek; Miranda Mugford; Ravindranath Tiruvoipati; Andrew Wilson; Elizabeth Allen; Mariamma M Thalanany; Clare L Hibbert; Ann Truesdale; Felicity Clemens; Nicola Cooper; Richard K Firmin; Diana Elbourne Journal: Lancet Date: 2009-09-15 Impact factor: 79.321